Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - triamcinolone acetonide 0.055%{relative};   - nasal spray suspension - 55 mcg/dose - active: triamcinolone acetonide 0.055%{relative}   excipient: benzalkonium chloride disodium edetate dihydrate dispersible cellulose glucose hydrochloric acid polysorbate 80 purified water sodium hydroxide - telnase is indicated for the treatment and prophylaxis of seasonal and perennial allergic rhinitis in adults and children over 6 years of age.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - ketoprofen 100mg - modified release capsule - 100 mg - active: ketoprofen 100mg excipient: colloidal silicon dioxide erythrosine ethylcellulose gelatin non pariel beads, maize starch + sucrose opacode white s-1-7020 patent blue v purified talc shellac sodium laurilsulfate titanium dioxide

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - clopidogrel bisulfate, form ii 97.875mg equivalent to 75 mg free base - film coated tablet - 75 mg - active: clopidogrel bisulfate, form ii 97.875mg equivalent to 75 mg free base excipient: carnauba wax hydrogenated castor oil hyprolose macrogol 6000 mannitol microcrystalline cellulose opadry pink 32k14834 - prevention of vascular ischaemia associated with secondary atherothrombotic events (mi, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome plavix is indicated in combination with aspirin for patients with: · unstable angina or non-st elevation mi. plavix is indicated for early and long-term reduction of atherothrombotic events (myocardial infarction, stroke, vascular death and refractory ischaemia) whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). · st-segment elevation acute myocardial infarction. in this population, plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - disopyramide 150mg (as base) - capsule - 150 mg - active: disopyramide 150mg (as base) excipient: gelatin magnesium stearate maize starch purified talc starch titanium dioxide

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - tiaprofenic acid 200mg - tablet - 200 mg - active: tiaprofenic acid 200mg

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - tiaprofenic acid 300mg - tablet - 300 mg - active: tiaprofenic acid 300mg

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - alimemazine tartrate 0.6%{relative};  ; alimemazine tartrate 0.6%{relative} - syrup - 30 mg/5ml - active: alimemazine tartrate 0.6%{relative}   excipient: ascorbic acid citric acid as monohydrate ethanol prunus armeniaca purified water sodium benzoate sodium citrate dihydrate sodium metabisulfite sodium sulfite sucrose active: alimemazine tartrate 0.6%{relative} excipient: ascorbic acid citric acid monohydrate ethanol prunus armeniaca purified water sodium benzoate sodium citrate dihydrate sodium metabisulfite sodium sulfite sucrose - · urticaria

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]);  ; influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]);  ; influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]);   - solution for injection - 10µg/15µg/15µg per dose - active: influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)])   influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)])   influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)])   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin sodium chloride water for injection

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b );  ; influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275);  ; influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 );   - solution for injection - 0.5 ml - active: influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b )   influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275)   influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 )   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin potassium chloride sodium chloride water for injection - vaxigrip is indicated for the prevention of influenza caused by influenza virus types a and b in adults and children aged 6 months and over.

Izrael - engleski - Ministry of Health

sanofi israel ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 100 mg/ml ml - enoxaparin - enoxaparin - clexane is indicated in adults for: • prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).